Confirmation of R132H mutation of isocitrate dehydrogenase 1 as an independent prognostic factor in anaplastic astrocytoma
- 191 Downloads
Identification of mutations affecting codon 132 of the enzyme cytosolic isocitrate dehydrogenase 1 (IDH1) in astrocytomas, oligodendrogliomas and secondary glioblastomas has influenced current concepts of diffuse gliomas. A recent study published in this journal demonstrated that in anaplastic astrocytomas and glioblastomas IDH1 mutation status better reflected patient prognosis than histological diagnosis according to the current WHO classification system . Even more intriguingly, patients with IDH1 wild type anaplastic astrocytomas demonstrated not only shorter overall survival (OS) when compared to IDH1 mutant anaplastic astrocytoma patients, but even survived shorter than patients with IDH1 mutant glioblastoma. Results were based on data from the NOA-04 trial  and the German Glioma Network .
KeywordsAstrocytoma Anaplastic Astrocytoma MGMT Promoter Methylation MGMT Promoter Methylation Status IDH1 Wild Type
- 3.Hartmann C, Hentschel B, Wick W et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707–718PubMedCrossRefGoogle Scholar